In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

This publication has 12 references indexed in Scilit:

• Direct 99mTc labeling of Herceptin (trastuzumab) by 99mTc(I) tricarbonyl ion
  Applied Radiation and Isotopes, 2008
• Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro
  Breast Cancer Research and Treatment, 2006
• Trastuzumab
  Drugs, 2006
• Herceptin: mechanisms of action and resistance
  Cancer Letters, 2005
• Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
  Nuclear Medicine and Biology, 2005
• Preclinical characterisation of ¹¹¹In‐DTPA‐trastuzumab
  British Journal of Pharmacology, 2004
• Monoclonal antibodies as therapeutic agents for cancer
  The Lancet Oncology, 2004
• Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
  Nature Biotechnology, 2004
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
  Nature, 2003
• Steps toward High Specific Activity Labeling of Biomolecules for Therapeutic Application: Preparation of Precursor [¹⁸⁸Re(H₂O)₃(CO)₃]⁺ and Synthesis of Tailor-Made Bifunctional Ligand Systems
  Bioconjugate Chemistry, 2002